Clinical effect of fludarabine combined with cyclophosphamide on chronic lymphocytic leukemia
10.13699/j.cnki.1001-6821.2016.04.006
- VernacularTitle:氟达拉滨联合环磷酰胺对慢性淋巴细胞白血病的临床疗效研究
- Author:
Hai-Long YUAN
1
;
Aizezi GULIBADANMU·
;
Hai-Zhou CAO
;
Gang CHEN
;
Jian-Hua QU
Author Information
1. 新疆医科大学 第一附属医院 血液病中心一病区
- Keywords:
fludarabine;
cyclophosphamide;
chronic lymphocytic leukemia;
Th17;
Treg cell
- From:
The Chinese Journal of Clinical Pharmacology
2016;(4):306-308
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluated the clinical efficacy of fludarabine combined with cyclophosphamide on chronic lymphocytic leukemia and the effect on peripheral blood Th 17 and Treg cell ratio.Methods Two hundred patients were randomly divided into control group ( n=100 ) and treatment group ( n=100 ).Patients in control group intravenously given fludarabine 25 mg · m-2 on 1 -3 d; patients in treatment group were intravenously given fludarabine 25 mg · m-2 and cyclophosphamide 250 mg· m-2 on 1 -3 d.A cycle of both groups were 4 weeks, and all treated for 2 cycles.The clinical efficacy , incidence of adverse drug reactions, and the ratio of Th17 and Treg cells in peripheral blood were observed .Results The total improvement rate of treatment group was 98.0%, higher than that in control group , which was 72.0%( P<0.05).The incidence of adverse drug reactions in treatment group was 8.0%, significantly lower than 29.0% in control group (P<0.05).The Th17 cells and Treg cells in treatment group were significantly better than those in control group ( P <0.05 ) .Conclusion Fludarabine combined with cyclophosphamide had a good clinical efficiency on chronic lymphocytic leukemia , which reduced the risk of adverse reactions and can significantly improve the Th 17 and Treg cells in peripheral blood.
